retatrutide nejm 2023 obesity trial ly3437943 Retatrutide: A Triple Agonist Shaping the Future of Metabolic Care Retatrutide (LY3437943), a Novel GIP/GLP-1/Glucagon
Description
Injecting at night, particularly after dinner, could theoretically affect overnight blood glucose patterns differently than morning injection after breakfast
MET-097i - monthly injectable GLP-1 Phase 2 shows ~14% weight loss at 28 weeks with good tolerability
Siddhanti, S
Les GLP1-RA ont-ils un effet sur les pilules contraceptives
